Identifying the Prevalence and Causes of 30-Day Hospital Readmission in Children: A Case Study from a Tertiary Pediatric Hospital [0.03%]
确定三级儿科医院中儿童30天再次住院的发生率和原因：一个病例研究
Hamad AlKhalaf,Wejdan AlHamdan,Sondos Kinani et al.
Hamad AlKhalaf et al.
Introduction: The objectives of this study were to determine the prevalence of unplanned readmissions in the pediatric population within 30 days of discharge, identify the possible reasons behind them, and develop a predi...
Letter to Editor: Implementation of Patient and Family Communication Model in Different Settings [0.03%]
致编辑的信：不同环境下患者及家属交流模式的实施
Abdul Rahman Jazieh
Abdul Rahman Jazieh
Assessing the Feasibility and Effects of Introducing the USA National Surgical Quality Improvement Program on Clinical Outcomes and Cost in Saudi Arabia: An Observational Study [0.03%]
在美国外科质量改进项目对沙特阿拉伯临床结果和成本的影响及可行性的评价：观察性研究
Shahenaz Najjar,Adel F Almutairi,Rashad Massoud et al.
Shahenaz Najjar et al.
Introduction: This study aimed at introducing a systematic clinical registry to assess the outcomes of surgical performances and the associated costs of surgical complications in hospitals of Saudi Arabia. ...
Determinants of Hospital-based Physician Participation in Quality Improvement: A Survey of Hospitalists in British Columbia, Canada [0.03%]
基于医院的医师参与质量改善的决定因素：加拿大不列颠哥伦比亚省医院医生的调查研究
Vandad Yousefi,Alaleh Asghari-Roodsari,Sarah Evans et al.
Vandad Yousefi et al.
Objective: We aimed to understand the extent of hospitalist involvement in system improvement efforts across the province of British Columbia in Canada and provide insights into determinants of such participation. ...
An Approach to Identify "Right" Problems for Initial Quality Improvement Projects [0.03%]
一种识别初期质量改善项目“正确”问题的方法
Sergio R Gutiérrez Ubeda
Sergio R Gutiérrez Ubeda
Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [0.03%]
从实际角度出发探讨沙特阿拉伯生物仿制药在肿瘤-血液学中所起的作用及其发展趋势
Mansoor A Khan,Mohammed A Aseeri,Majed A Alshamrani et al.
Mansoor A Khan et al.
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients. Thi...
Abrar Al-Subhi,Mansoor Ahmed Khan,Mohammed A Aseeri
Abrar Al-Subhi
Introduction: Medication-use evaluation (MUE) is a performance improvement method used to achieve optimal patient outcomes. The recombinant human factor VIIa (rFVIIa) (NovoSeven) is an expensive agent approved by the U.S....
Francisco Rocha-Gonçalves
Francisco Rocha-Gonçalves